GenVec to present at the Phacilitate Cell and Gene Conference in Barcelona this September - Here's an excerpt from the program:
Big Pharma players in Europe:
How are the large multinationals approaching the challenge of developing and manufacturing commercial ATMP products in Europe? What are the key differences with the US from pharma’s point of view? Includes companies focused on:
o Stem cell platforms, including iPS cell therapies and eSCs
o CARTs and other cellular immunotherapies
o Gene therapy
Panellists:
Jan Thirkettle, Vice President, Cell & Gene Therapy Platform, Biopharm R&D, GlaxoSmithKline
Dr Gregory MacMichael, Global Head of Advanced Therapies- Technology Research & Development,Novartis
Dr Sicco Popma, Scientific Director, Gene Modified Cell Therapies Janssen
Dr Joern-Peter Halle, Senior Vice President, Global Head of External Innovation, Merck Serono
Dr Carlos Plata, Chief Scientific Officer, Chief Medical Officer & Head of R&D, Esteve
Then:
Biotech showcase
4 leading ATMP biotech innovators reveal their latest data and progress in the development of their platform technologies
10.50 Genvec - Dr Bryan Butman, Senior Vice President Development, GenVec
11.00 Showcase 2
11.10 Showcase 3
11.20 Showcase 4
